Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Enbrel Liquid Immunogenicity Protocol
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2010-07-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 447
- Registration Number
- NCT00249041
Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2010-03-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 44
- Registration Number
- NCT00239239
A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)
Completed
- Conditions
- Nephrology
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1000
- Registration Number
- NCT00189501
Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD)
Phase 3
Terminated
- Conditions
- Chronic Kidney Disease
- Interventions
- Drug: Epoetin alfa RBDrug: Epoetin alfa DT
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2008-07-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 850
- Registration Number
- NCT00156962
EPO Deep Tank in Dialysis Subjects
Phase 3
Completed
- Conditions
- Chronic Kidney Disease
- Interventions
- Drug: Epoetin alfa DT
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2010-02-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 580
- Registration Number
- NCT00156949
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
Phase 1
Completed
- Conditions
- Waldenstrom's MacroglobulinemiaNon-Hodgkin's LymphomaHodgkin's DiseaseMultiple Myeloma
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 48
- Registration Number
- NCT00150462
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Tower Cancer Research Foundation, Beverly Hills, California, United States
A Multi-Center, Observational Safety Registry of Subjects With Idiopathic Parkinson's Disease Previously Treated With Intraputaminal Infusion of Liatermin
Completed
- Conditions
- Idiopathic Parkinson's Disease
- Interventions
- Drug: Safety observation
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2010-02-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 31
- Registration Number
- NCT00148369
Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.
Phase 3
Completed
- Conditions
- Anemia
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2013-05-15
- Lead Sponsor
- Amgen
- Registration Number
- NCT00148421
Efficacy of Epoetin Alfa Deep Tank in Treatment of Anemia in Patients With Chronic Kidney Disease Receiving Hemodialysis
Phase 3
Completed
- Conditions
- Nephrology
- Interventions
- Drug: Epoetin alfa RBDrug: Epoetin alfa DT
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2010-02-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 420
- Registration Number
- NCT00146224
Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy
Phase 2
Completed
- Conditions
- AnemiaCancer
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2013-05-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 750
- Registration Number
- NCT00144131
© Copyright 2025. All Rights Reserved by MedPath